| Shahryar Mousavi, MD | |
|
24953 Paseo De Valencia, #3a, Laguna Hills, CA 92653-4342 | |
| (949) 297-3838 | |
| Not Available |
| Full Name | Shahryar Mousavi |
|---|---|
| Gender | Male |
| Speciality | Interventional Pain Management |
| Experience | 23 Years |
| Location | 24953 Paseo De Valencia, Laguna Hills, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023263282 | NPI | - | NPPES |
| CB235450 | Other | CA | MEDICARE PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | A128033 (California) | Primary |
| 207L00000X | Anesthesiology | A128033 (California) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Afshin Gerayli Md A Professional Corporation | 0345321634 | 3 |
News Archive
ReCor Medical, an emerging medical device company, announced today that its PARADISE (Percutaneous Renal Denervation System) ultrasound platform for achieving renal denervation has received the CE mark. PARADISE is designed to treat patients with 'resistant' hypertension, a major risk factor for cardiovascular disease.
Single-letter genetic variations within parts of the genome once dismissed as 'junk DNA' can increase cancer risk through wormhole-like effects on far-off genes, new research shows.
Exposure to environmental chemicals, especially early in life, is an important contributing factor in the development of breast cancer, according to the most comprehensive review of human studies to date.
What has been revealed is that the systems set up during an industrial era to provide health care, retirement income and support during economic downturns are inadequate for and ill-suited to our post-industrial, globalized economy. ...one can imagine a system in which all workers and nonworkers are required to buy insurance from the government-regulated exchanges being set up in each region or state under the Obama health-care reform plan.
Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results published in the September, 2009 edition of THE JOURNAL OF UROLOGY(R) from the OrBIT trial of its Urgent PC System.
› Verified 8 days ago
| Entity Name | Afshin Gerayli Md A Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366636045 PECOS PAC ID: 0345321634 Enrollment ID: O20080111000634 |
News Archive
ReCor Medical, an emerging medical device company, announced today that its PARADISE (Percutaneous Renal Denervation System) ultrasound platform for achieving renal denervation has received the CE mark. PARADISE is designed to treat patients with 'resistant' hypertension, a major risk factor for cardiovascular disease.
Single-letter genetic variations within parts of the genome once dismissed as 'junk DNA' can increase cancer risk through wormhole-like effects on far-off genes, new research shows.
Exposure to environmental chemicals, especially early in life, is an important contributing factor in the development of breast cancer, according to the most comprehensive review of human studies to date.
What has been revealed is that the systems set up during an industrial era to provide health care, retirement income and support during economic downturns are inadequate for and ill-suited to our post-industrial, globalized economy. ...one can imagine a system in which all workers and nonworkers are required to buy insurance from the government-regulated exchanges being set up in each region or state under the Obama health-care reform plan.
Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results published in the September, 2009 edition of THE JOURNAL OF UROLOGY(R) from the OrBIT trial of its Urgent PC System.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shahryar Mousavi, MD 35 Creek Rd, Irvine, CA 92604-4724 Ph: (315) 464-4889 | Shahryar Mousavi, MD 24953 Paseo De Valencia, #3a, Laguna Hills, CA 92653-4342 Ph: (949) 297-3838 |
News Archive
ReCor Medical, an emerging medical device company, announced today that its PARADISE (Percutaneous Renal Denervation System) ultrasound platform for achieving renal denervation has received the CE mark. PARADISE is designed to treat patients with 'resistant' hypertension, a major risk factor for cardiovascular disease.
Single-letter genetic variations within parts of the genome once dismissed as 'junk DNA' can increase cancer risk through wormhole-like effects on far-off genes, new research shows.
Exposure to environmental chemicals, especially early in life, is an important contributing factor in the development of breast cancer, according to the most comprehensive review of human studies to date.
What has been revealed is that the systems set up during an industrial era to provide health care, retirement income and support during economic downturns are inadequate for and ill-suited to our post-industrial, globalized economy. ...one can imagine a system in which all workers and nonworkers are required to buy insurance from the government-regulated exchanges being set up in each region or state under the Obama health-care reform plan.
Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results published in the September, 2009 edition of THE JOURNAL OF UROLOGY(R) from the OrBIT trial of its Urgent PC System.
› Verified 8 days ago